Overview

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

Status:
Not yet recruiting
Trial end date:
2036-08-09
Target enrollment:
Participant gender:
Summary
The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.
Phase:
Phase 4
Details
Lead Sponsor:
Janssen Research & Development, LLC